PATIENT-SAFETY-MOVEMENT
9.5.2018 16:32:11 CEST | Business Wire | Press release
The Australian and New Zealand College of Anaesthetists (ANZCA) is partnering with the Patient Safety Movement Foundation (PSMF) in support of the mission to eliminate medical errors within hospitals - the 14 th leading cause of death worldwide. The announcement was made publicly at ANZCA’s Annual Scientific Meeting (ASM) in Sydney on May 8, 2018. Dr. Michael A. E. Ramsay, Anaesthetist, and Patient Safety Movement Foundation Board Member was present to sign the Commitment to Action Letter publicly alongside ANZCA President, Professor David A. Scott.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180509005874/en/
“We are thrilled to have the Australian and New Zealand College of Anaesthetists join us in our fight to eliminate preventable harm from hospitals. Through this partnership, we will reach the next generation of anaesthetists and recruit two important countries in our global effort to improve patient safety through the implementation of evidence-based processes,” explains Joe Kiani, Founder and Chairman of the Patient Safety Movement Foundation.
ANZCA runs one of Australasia’s largest specialist medical colleges and is the professional organisation representing nearly 6400 specialist anaesthetists and 1500 anaesthetists in training. ANZCA’s commitment represents the first by a major partner in Australia or New Zealand and joins 4,598 other committed hospitals and partners in 44 countries working towards the goal of eliminating preventable harm in hospitals.
“Patient harm and patient deaths occur in our hospitals daily, despite our best intentions. Many of these events are preventable if we apply existing knowledge, especially with the aid of new technologies. ANZCA welcomes this partnership which recognises our joint commitment to safety and quality in our specialty and improving patient safety,” said Professor Scott. “Initiatives such as this are so important for patients, hospitals and the specialty of anaesthesia.”
As a Committed Partner, ANZCA will work with the PSMF to improve patient outcomes with an acute focus on anesthesiology and perioperative care. Actions include:
| a. | Spreading the PSMF mission to ANZCA members; | |||
| b. | Identifying Actionable Patient Safety Solutions (APSS) that align with ANZCA’s standards and/or policies and inviting members working in hospitals to implement APSS or similar processes with the aim of eliminating preventable patient deaths in hospitals; | |||
| c. | Annually disseminating relevant APSS to ANZCA members; | |||
| d. | Engaging with the PSMF at its annual meetings to develop and improve relevant APSS. | |||
To learn more about the Patient Safety Movement Foundation, please visit www.patientsafetymovement.org .
About Patient Safety Movement Foundation: More than 200,000 people die every year in U.S. hospitals and 4.8 million worldwide in ways that could have been prevented. The Patient Safety Movement Foundation is a global non-profit which creates free tools for patients and hospitals. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to ZERO by 2020 (0X2020™). Improving patient safety will require a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The Patient Safety Movement Foundation works with all stakeholders to address the problems with actionable solutions for patient safety. The Foundation also convenes the World Patient Safety, Science & Technology Summit. The Summit brings together some of the world’s best minds for thought-provoking discussions and new ideas to challenge the status quo. By presenting specific, high-impact solutions to meet patient safety challenges, called Actionable Patient Safety Solutions, encouraging medical technology companies to share the data their products are purchased for, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions, the Patient Safety Movement Foundation is working toward ZERO preventable deaths by 2020. Visit patientsafetymovement.org.
About ANZCA: The Australian and New Zealand College of Anaesthetists (ANZCA) is the professional organisation for about 6400 specialist anaesthetists (Fellows) and 1500 anaesthetists in training (trainees). One of Australia's largest specialist medical colleges, ANZCA, along with its Faculty of Pain Medicine, is responsible for the training, examination and specialist accreditation of anaesthetists and pain medicine specialists and the standards of clinical practice in Australia and New Zealand. The College also plays a significant role in the advancement of anaesthesia in southeast Asia and South Pacific island countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180509005874/en/
Contact:
Patient Safety Movement Foundation
Tanya Lyon, Public Relations
Manager
(949) 351-2858
tanya.lyon@patientsafetymovement.org
or
Australian
& New Zealand College of Anaesthetists
Carolyn Jones, Media
Manager
+61 3 8517 5303
cjones@anzca.edu.au
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
